US · RXST
RxSight, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Aliso Viejo, CA 92656
- Website
- rxsight.com
Price · as of 2025-12-31
$7.40
Market cap 307.55M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.21 | +294.73% |
| Intrinsic Value(DCF) | $4.81 | -35% |
| Graham-Dodd Method(GD) | $1.97 | -73.43% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $779.26 | |||
| 2021 | $12.85 | $33.39 | $7.14 | $0.00 | $0.00 |
| 2022 | $14.52 | $34.44 | $64,286.90 | $0.00 | $0.00 |
| 2023 | $52.55 | $52.38 | $13,191.53 | $0.00 | $0.00 |
| 2024 | $25.10 | $45.09 | $6,114.40 | $3.70 | $0.00 |
| 2025 | $7.61 | $29.21 | $19.28 | $1.97 | $0.00 |
AI valuation
Our deep-learning model estimates RxSight, Inc.'s (RXST) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.21
- Current price
- $7.40
- AI upside
- +294.73%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.81
-35% upside
Graham-Dodd
$1.97
-73.43% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RXST | RxSight, Inc. | $7.40 | 307.55M | +295% | -35% | -73% | — | — | 1.14 | 2.33 | -2.43 | — | 1.14 | 76.60% | -35.84% | -28.96% | 0.00% | -83.88% | 0.00% | 0.04 | -1204.75 | 10.95 | 9.58 | 0.22 | 3380.00% | -389.00% | -1360.00% | -6.17% | -0.59 | -33.66% | 0.00% | — | 1.44% | -2.00 | -4.98 | 0.72 | 3.16 |
| BFLY | Butterfly Network, Inc. | $3.79 | 957.36M | +668% | -29% | — | — | -12.35 | 4.85 | 9.75 | -12.15 | — | 5.05 | 46.85% | -88.53% | -78.95% | -42.25% | -104.05% | -27.89% | 0.09 | -58.00 | 3.83 | 2.72 | 1.97 | -882.00% | 1896.00% | -6386.00% | -1.69% | -0.20 | -19.32% | 0.00% | 0.00% | 7.02% | -9.47 | -51.01 | 8.39 | 1.64 |
| CERS | Cerus Corporation | $2.56 | 491.74M | +1,048% | -13% | — | — | -13.30 | 4.96 | 1.55 | -29.56 | — | 5.08 | 55.21% | -7.89% | -11.60% | -38.53% | -18.17% | -10.52% | 1.75 | -1.60 | 2.39 | 1.73 | -7.76 | -4762.00% | 1529.00% | -11784.00% | 3.06% | 0.18 | 10.88% | 0.00% | 0.00% | 2.34% | -20.83 | 34.77 | 1.64 | -5.07 |
| DCTH | Delcath Systems, Inc. | $8.90 | 308.83M | +1,206% | — | — | — | 118.48 | 2.88 | — | 59.54 | — | 2.88 | 0.00% | — | — | 3.00% | 2.70% | 2.70% | 0.01 | — | 10.92 | 9.39 | -11.02 | -10756.00% | -10000.00% | -20899.00% | 6.56% | 2.06 | 111.33% | 0.00% | 0.00% | 3.63% | 348.16 | 10.96 | — | 10.54 |
| DMAC | DiaMedica Therapeutics In… | $7.95 | 414.02M | — | — | — | — | -9.54 | 5.73 | — | -7.11 | — | 5.73 | 0.00% | — | — | -53.27% | 1178.75% | -48.64% | 0.01 | — | 8.28 | 8.23 | 0.10 | 0.00% | — | 1786.00% | -9.48% | -4.10 | 976.41% | 0.00% | 0.00% | 0.00% | -7.10 | -8.57 | — | 19.75 |
| KIDS | OrthoPediatrics Corp. | $19.17 | 480.73M | +230% | -49% | -91% | — | -11.37 | 1.30 | 1.91 | -55.63 | -373.01 | 2.61 | 73.05% | -12.27% | -16.78% | -11.31% | -8.28% | -8.08% | 0.14 | -4.84 | 5.55 | 2.48 | -3.66 | 305.00% | 1545.00% | -6136.00% | -3.54% | -0.11 | -4.56% | 0.00% | 0.00% | 1.84% | -15.12 | -27.47 | 1.85 | 2.35 |
| NPCE | NeuroPace, Inc. | $14.58 | 485.63M | +102% | +40% | — | — | -11.80 | 39.98 | 4.01 | -20.57 | — | 39.98 | 73.94% | -27.12% | -33.97% | -189.35% | -78.53% | -26.83% | 9.15 | -2.46 | 5.37 | 4.33 | -3.61 | -2677.00% | 2214.00% | -815.00% | -5.70% | -1.18 | -66.15% | 0.00% | 0.00% | 0.00% | -15.73 | -18.68 | 4.27 | -4.71 |
| SMLR | Semler Scientific, Inc. | $20.33 | 310.75M | +321% | +54% | +196% | — | 6.57 | 1.17 | 4.78 | 11.81 | 6.92 | 16.68 | 91.55% | 37.19% | 72.65% | 27.04% | 15.50% | 25.73% | 0.00 | — | 3.59 | 3.06 | -0.41 | 9506.00% | -1744.00% | 1881.00% | 9.06% | 3.87 | 21.12% | 0.00% | 0.00% | 0.00% | 12.13 | 10.43 | 4.51 | 18.96 |
| SRDX | Surmodics, Inc. | $42.98 | 614.51M | +203% | -62% | -97% | — | -49.05 | 4.76 | 4.49 | 118.28 | -7.60 | 11.17 | 73.81% | -4.48% | -9.15% | -9.67% | -5.14% | -6.34% | 0.28 | -1.59 | 3.96 | 3.09 | -0.61 | 64545.00% | -491.00% | -14271.00% | -0.57% | 0.01 | -2.95% | 0.00% | 0.00% | 0.00% | -99.07 | -172.40 | 4.44 | 7.30 |
| TCMD | Tactile Systems Technolog… | $29.29 | 657.24M | +114% | +65% | -58% | -43% | — | 3.06 | 2.03 | 16.77 | — | 4.51 | 75.17% | 8.89% | 5.79% | 0.00% | 11.72% | 0.00% | 0.07 | 28.21 | 4.03 | 3.11 | -1.88 | 1714.00% | 1247.00% | 599.00% | 6.03% | 1.05 | 26.58% | 0.00% | — | 6.69% | 20.58 | 14.90 | 1.83 | 9.68 |
| TMCI | Treace Medical Concepts, … | $1.86 | 118.52M | +1,477% | -65% | — | — | -1.78 | 1.20 | 0.49 | -1.64 | -53.40 | 1.56 | 79.81% | -25.46% | -27.74% | -58.94% | -67.77% | -28.95% | 0.16 | -10.18 | 4.31 | 2.95 | -0.08 | 333.00% | 159.00% | -3953.00% | -28.08% | -0.52 | -36.90% | 0.00% | 0.00% | 52.40% | -1.30 | -2.40 | 0.33 | -0.40 |
About RxSight, Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
- CEO
- Ronald Kurtz
- Employees
- 498
- Beta
- 1.13
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.81 ÷ $7.40) − 1 = -35% (DCF, example).